Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
(China) Biocon (India) Altimmune (US) Viking Therapeutics (US) Recent Industry Developments January 2026: Novo Nordisk received US and EU regulatory approval for Wegovy High-Dose (7.2 mg), expanding treatment options within its obesity portfolio
Shop Medications , GLP-1, which stands for glucagon-like peptide-1, is a hormone your body naturally produces to help regulate blood sugar
However, these variations often lack robust clinical data to confirm their effectiveness and safety
More significantly, RA patients already on DMARDs (disease-modifying antirheumatic drugs) who added a GLP-1 agonist had fewer disease flares than those on DMARDs alone
Fan SH, Xiong QF, Wang L, Zhang LH, Shi YW
Higher-dose formulations of semaglutide (Wegovy, 2.4 mg weekly) and tirzepatide (Zepbound, up to 15 mg weekly) are approved specifically for chronic weight management in non-diabetic patients
US$ 22.14
US$ 25.69
US$ 21.70
US$ 26.80
US$ 22.31
US$ 26.04
